Background Genome-wide association studies have identified multiple risk variants for
psychiatric disorders. Nevertheless, how the risk variants confer risk of psychiatric disorders …

Schizophrenia is regarded as a neurodevelopmental disorder with its course progressing
throughout life. However, the aetiology and development of schizophrenia are still under …

Schizophrenia is a grave neuropsychiatric disease which frequently onsets between the end
of adolescence and the beginning of adulthood. It is characterized by a variety of …

Identifying genes whose expression is associated with schizophrenia (SCZ) risk by
transcriptome-wide association studies (TWAS) facilitates downstream experimental studies …

Patients with schizophrenia experience cognitive dysfunction and negative symptoms that
do not respond to current drug treatments. Historical evidence is consistent with the …

Background Schizophrenia (SCZ) is a debilitating psychiatric disorder with a large genetic
contribution; however, its neurodevelopmental substrates remain largely unknown …

The primary aim of precision medicine is to tailor healthcare more closely to the needs of
individual patients. This requires progress in two areas: the development of more precise …

Clinical and preclinical studies suggest that some of the behavioral alterations observed in
schizophrenia (SZ) may be mechanistically linked to synaptic dysfunction of glutamatergic …

With new data about different aspects of schizophrenia being continually generated, it
becomes necessary to periodically revisit exactly what we know. Along with a need to review …

Integrating findings from genome-wide association studies with molecular datasets can help
develop insight into the underlying functional mechanisms responsible for trait-associated …